Institution
National Jewish Health
Healthcare•Denver, Colorado, United States•
About: National Jewish Health is a healthcare organization based out in Denver, Colorado, United States. It is known for research contribution in the topics: T cell & Asthma. The organization has 883 authors who have published 833 publications receiving 79201 citations. The organization is also known as: National Jewish Medical and Research Center.
Topics: T cell, Asthma, Population, Lung, Antigen
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The hypothesis that Gal-3 predicts pulmonary artery pressure and right ventricular function in pulmonary arterial hypertension (PAH) is tested using a prospective study on 15 subjects with right heart failure.
4 citations
••
01 Jan 2012TL;DR: This chapter offers an explanation and application of commonly used techniques, considerations for vocal hygiene and abuse/misuse, questions for comprehension, and case studies with video presentations.
Abstract: Speech therapy for the treatment of functional respiratory disorders serves as an efficient and effective means to resolving vocal cord dysfunction, chronic cough, and dysfunctional breathing patterns. Education regarding the laryngeal and respiratory mechanisms is an essential first step in treating such disorders. Various speech therapy techniques are tailored to the individual patient’s needs and trigger situations. As the patient population is homogenous in diagnosis, but diverse in etiologies, triggers and contributing factors, specialized training in treatment techniques aids the clinician in recognizing treatment barriers, ways to desensitize hyper-functional respiratory responses, and ensures their ultimate resolution. This chapter offers an explanation and application of commonly used techniques, considerations for vocal hygiene and abuse/misuse, questions for comprehension, and case studies with video presentations.
4 citations
••
TL;DR: ATAQ-LAM is a disease-specific instrument designed to assess HRQL in LAM patients and should have a four-domain structure, according to the Rasch model, which indicates greater impairment in HRQL.
Abstract: Background
Lymphangioleiomyomatosis (LAM) is a progressive lung disease that impairs health-related quality of life (HRQL).
4 citations
••
TL;DR: Using cell type deconvolution to study immune cell subpopulations, subjects with COPD had a lower proportion of CD4+ resting memory cells and naive B cells compared to non-COPD smokers, suggesting a critical role for immune response in long-term COPD outcomes.
Abstract: The progression of chronic obstructive pulmonary disease (COPD) is associated with marked alterations in circulating immune cell populations, but no studies have characterized alterations in these cell types across the full spectrum of lung function impairment in current and former smokers. In 6,299 subjects from the COPDGene and ECLIPSE studies, we related Coulter blood counts and proportions to cross-sectional FEV1 adjusting for current smoking status. We also related cell count measures to three-year change in FEV1 in ECLIPSE subjects. In a subset of subjects with blood gene expression data, we used cell type deconvolution methods to infer the proportions of immune cell subpopulations, and we related these to COPD clinical status. We observed that FEV1 levels are positively correlated with lymphocytes and negatively correlated with myeloid populations such as neutrophils and monocytes. In multivariate models, cell counts and proportions were significantly associated with FEV1. We also observed that lymphocytes, monocytes, and eosinophil counts were predictive of three year change in lung function. Using cell type deconvolution to study immune cell subpopulations, we observed that subjects with COPD had a lower proportion of CD4+ resting memory cells and naive B cells compared to non-COPD smokers. Alterations in circulating immune cells in COPD support a mixed pattern of lymphocyte suppression and an enhanced myeloid cell immune response. Cell counts and proportions contribute independent information to models predicting lung function suggesting a critical role for immune response in long-term COPD outcomes. Cell type deconvolution is a promising method for immunophenotyping in large cohorts.
4 citations
•
27 Dec 1996TL;DR: In this article, a method to limit infection by an immunodeficiency virus (IDV) is discussed. The method includes inhibiting an immunoveficiency Virus protein which regulates apoptosis in cells.
Abstract: Disclosed is a method to limit infection by an immunodeficiency virus. The method includes inhibiting an immunodeficiency virus protein which regulates apoptosis in cells. Also disclosed are methods to identify compounds that regulate cellular inhibitors of apoptosis in cells infected with an immunodeficiency virus and compounds identified thereby.
4 citations
Authors
Showing all 901 results
Name | H-index | Papers | Citations |
---|---|---|---|
Thomas V. Colby | 126 | 501 | 60130 |
John W. Kappler | 122 | 464 | 57541 |
Donald Y.M. Leung | 121 | 614 | 50873 |
Philippa Marrack | 120 | 416 | 54345 |
Jeffrey M. Drazen | 117 | 693 | 52493 |
Peter M. Henson | 112 | 369 | 54246 |
David A. Schwartz | 110 | 958 | 53533 |
David A. Lynch | 108 | 714 | 59678 |
Norman R. Pace | 101 | 297 | 50252 |
Kevin K. Brown | 100 | 387 | 47219 |
Stanley J. Szefler | 99 | 554 | 37481 |
Erwin W. Gelfand | 99 | 675 | 36059 |
James D. Crapo | 98 | 473 | 37510 |
Yang Xin Fu | 97 | 390 | 33526 |
Stephen D. Miller | 94 | 433 | 30499 |